Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-small Cell Lung Cancer.

Wei J, Liu LK, Gao W, Zhu CJ, Liu YQ, Cheng T, Shu YQ.

Chin J Cancer Res. 2011 Jun;23(2):123-8. doi: 10.1007/s11670-011-0123-2.

2.

Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer.

Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, Shu YQ.

Chin J Cancer. 2011 Jun;30(6):407-14.

3.
4.

Decreased circulating miR-375: A potential biomarker for patients with non-small-cell lung cancer.

Yu H, Jiang L, Sun C, Guo L, Lin M, Huang J, Zhu L.

Gene. 2013 Oct 24. pii: S0378-1119(13)01419-4. doi: 10.1016/j.gene.2013.10.024. [Epub ahead of print]

PMID:
24513341
5.

Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.

Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y.

Biomed Pharmacother. 2010 Jul;64(6):399-408. doi: 10.1016/j.biopha.2010.01.018. Epub 2010 Feb 25.

PMID:
20363096
6.

Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.

Yuxia M, Zhennan T, Wei Z.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2045-50. doi: 10.1007/s00432-012-1285-0. Epub 2012 Jul 18.

PMID:
22806310
7.

High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer.

Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH, Zhang YK.

Med Oncol. 2012 Jun;29(2):618-26. doi: 10.1007/s12032-011-9923-y. Epub 2011 Apr 24.

PMID:
21516486
8.

MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer.

Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y.

Cancer Biol Ther. 2012 Mar;13(5):330-40. doi: 10.4161/cbt.19073. Epub 2012 Mar 1.

PMID:
22237007
9.

Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls.

Szpechcinski A, Dancewicz M, Kopinski P, Kowalewski J, Chorostowska-Wynimko J.

Eur J Med Res. 2009 Dec 7;14 Suppl 4:237-40.

10.

Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR.

Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES.

Clin Chem. 2008 Oct;54(10):1696-704. doi: 10.1373/clinchem.2007.101741. Epub 2008 Aug 21.

11.

[Analysis of the relationship between the response after the First-line chemotherapy and the survival in the advanced non-small cell lung cancer.].

Lin L, Xiang X, Huang H, Zhao H, Zhang Y, Wu J, Zhao Y, Wu X, Zhang L.

Zhongguo Fei Ai Za Zhi. 2008 Jun 20;11(3):333-8. doi: 10.3779/j.issn.1009-3419.2008.03.015. Chinese.

12.

Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.

Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M.

J Clin Oncol. 2009 Apr 20;27(12):2030-7. doi: 10.1200/JCO.2008.19.4134. Epub 2009 Mar 9.

PMID:
19273703
13.

Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer.

Zhang H, Mao F, Shen T, Luo Q, Ding Z, Qian L, Huang J.

Oncol Lett. 2017 Feb;13(2):669-676. doi: 10.3892/ol.2016.5462. Epub 2016 Dec 6.

14.

Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis.

Devriese LA, Bosma AJ, van de Heuvel MM, Heemsbergen W, Voest EE, Schellens JH.

Lung Cancer. 2012 Feb;75(2):242-7. doi: 10.1016/j.lungcan.2011.07.003. Epub 2011 Aug 4.

PMID:
21820198
15.

Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening.

Li L, Guo Z, Wang J, Mao Y, Gao Q.

Dig Dis Sci. 2012 Nov;57(11):2910-6. doi: 10.1007/s10620-012-2317-y. Epub 2012 Aug 5.

PMID:
22865399
16.

Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer.

Dou H, Wang Y, Su G, Zhao S.

Int J Clin Exp Med. 2015 Jun 15;8(6):9291-8. eCollection 2015.

17.

DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer.

Wang Z, Chen Z, Gao Y, Li N, Li B, Tan F, Tan X, Lu N, Sun Y, Sun J, Sun N, He J.

Cancer Biol Ther. 2011 Mar 1;11(5):490-6. doi: 10.4161/cbt.11.5.14550.

PMID:
21383543
18.

Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer.

Roa WH, Kim JO, Razzak R, Du H, Guo L, Singh R, Gazala S, Ghosh S, Wong E, Joy AA, Xing JZ, Bedard EL.

Clin Invest Med. 2012 Oct 6;35(5):E271.

PMID:
23043708
19.

The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer.

Du YZ, Gu XH, Li L, Gao F.

J Surg Oncol. 2011 Dec;104(7):836-40. doi: 10.1002/jso.21948. Epub 2011 Jun 7.

PMID:
21656524
20.

Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.

Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E.

Chest. 1995 Jul;108(1):163-9.

PMID:
7541742

Supplemental Content

Support Center